Baricitinib d5

Baricitinib d5 is a deuterated version of Baricitinib, a medication approved by the US FDA for the treatment of rheumatoid arthritis. Baricitinib d5 is a selective inhibitor of Janus kinase (JAK) 1 and JAK 2, two enzymes that play a key role in the inflammatory response. By inhibiting JAK 1 and JAK 2, Baricitinib d5 reduces inflammation, joint damage, and pain in patients with rheumatoid arthritis. Baricitinib d5 has a molecular formula of C16D5N7O and a molecular weight of 323.42 g/mol. It is available in the form of a white to off-white crystalline powder that is sparingly soluble in water. The deuterated version of Baricitinib has five deuterium atoms replacing five hydrogen atoms in the molecule. The recommended dosage of Baricitinib d5 is 2 mg once daily for patients with rheumatoid arthritis. It is usually taken orally with or without food. The medication should be used with caution in patients with a history of tuberculosis, hepatitis B or C, or other infections. Baricitinib d5 should not be used in patients who have an active or serious infection. In conclusion, Baricitinib d5 is an effective medication for the treatment of rheumatoid arthritis. Its selective inhibition of JAK 1 and JAK 2 makes it an attractive therapeutic option for patients with this condition. The deuterated version of Baricitinib provides an alternative option for patients who may require a more customized treatment approach.